Drugs / Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter
Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03017820 | Apr 2017 → Dec 2028 expected | B-cell non-Hodgkin lymphoma, acute myeloid leukemia, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma +5 | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07510334 | Apr 2026 → Aug 2033 expected | clear cell renal carcinoma | Mayo Clinic | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03017820 ↗ |
| Route | Intravenous | “intravenous (IV) VSV-IFNβ-NIS” NCT03017820 ↗ |